Arthralgia in South Indian patients with pulmonary tuberculosis during treatment with pyrazinamide and rifampicin.
Nazareth, O.; Acharyulu, G.S.; Janardhanam, B.; Krishnamurthy, P.V.; Parthasarathy, R.; Prema Devadatta; Raghupati Sarma, G.; Rani Balasubramanian; Ramakrishnan, C.V.; Santha, T.; Tripathy, S.P.
Lung India; 1984; II; 231-236.
Arthralgia was the major adverse reaction encountered in a clinical trial of the treatment of pulmonary tuberculosis with three short-course regimens containing pyrazinamide in South Indian patients. The first regimen was of rifampicin, streptomycin, isoniazid and pyrazinamide given daily for three months; the second was of the same four drugs daily for three months followed by streptomycin, isoniazid and pyrazinamide twice-weekly for two months, and the third was the same as the second except that rifampicin was not administered. Arthralgia was reported in 38% of 363 rifampicin patients and 68% of 179 non-rifampicin patients, highly significant difference (p<0.001). The onset of arthralgia was mostly during the first two months of chemotherapy. The knees were affected in about 90% followed by the ankles in about 50% of the patients with arthralgia, and about 60% of these patients had one or more of the signs, swelling, tenderness and limitation of joint movement. Chemotherapy was modified in 10 rifampicin and 15 non-rifampicin patients; the rest of the patients were managed with symptomatic treatment with analgesics. There was a two to three fold increase in serum uric acid concentrations by the end of the first month and the concentrations were more or less stationary throughout the rest of the daily phase of treatment. The mean concentration during the daily phase of treatment in patients with arthralgia (0.482 mmoles/litre) was similar to that in those without arthralgia 0.484 mmoles/litre), while that in the rifampicin patients (0.476 mmoles/litre) was significantly lower (p=0.03) than that in the non-rifampicin patients (0.495 mmoles/litre).
Back to List of publications / Home |